Trial met primary endpointAZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 11 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 October 2021 06:11:04 UTC.